BioPharma Credit PLC USD · LSE:BPCP
BioPharma Credit PLC USD — BioPharma Credit — Investor Presentation (September 2019)
15 slides from BioPharma Credit PLC USD's investor presentation, September 2019
Slide 1: Debt Capital for the Life Sciences Industry
Debt Capital for the Life Sciences Industry COMPANY PRESENTATION – September 2019 For additional information please email: ir@bpcruk.com or visit BioPharma Credit’s website at www.bpcruk.com
Slide 2: Disclaimer
Disclaimer . THIS PRESENTATION IS BEING PROVIDED TO YOU SOLELY FOR YOUR INFORMATION. THIS PRESENTATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDIC
Slide 3: Disclaimer
Disclaimer This presentation was prepared using the financial information available to the Company as at the date of this presentation. Except where otherwise indicated herein, the information provided in this presentation is based on matters as they exist as of the date of preparation and not as of
Slide 4: Financial Highlights
Financial Highlights1 1 Excerpt from the Company’s Half-Yearly Report for the period ended 30 June 2019. 3
Slide 5: Financial Highlights
Financial Highlights1 1 Excerpt from the Company’s Half-Yearly Report for the period ended 30 June 2019. 4
Slide 6: Portfolio and Dividends since IPO
Portfolio and Dividends since IPO2 Evolution of the BioPharma Credit portfolio (millions) BPCR Portfolio Composition ($m) $1,600 • ~ $339m or 100% of seed assets Cash (RPS + BP-III) have amortized $21 $1,400 RPS since IPO $83 $150 $1,200 $150 BioPharma III • ~$1,100m deployed across nine $64 $103 ne
Slide 7: Major milestones since IPO
Major milestones since IPO1 Total Raised for BPCR2 IPO – $762m gross Placing of Ordinary Issue of C- Placing of Ordinary ~$1,385m gross proceeds including Shares – $154m Shares – Shares – $305m proceeds $339m of seed gross proceeds $163m gross gross proceeds assets proceeds ($1,045m in cash) March 2
Slide 8: The majority of new drugs approved originated at smaller biopharma companies
The majority of new drugs approved originated at, or were initially developed by, smaller biopharma companies 7 Source: Pharmakon Advisors
Slide 9: Summary of Past Transactions
Summary of Past Transactions 8
Slide 10: $25m equity plus up to $80m senior secured corporate loan to BioDelivery Sciences
$25m equity plus up to $80m senior secured corporate loan to BioDelivery Sciences BioDelivery Sciences Corporate Overview Description of key products Description: BioDelivery Sciences International, Inc. (”BDSI") is a BELBUCA (buprenorphine buccal film) – approved in October 2015 specialty pharm
Slide 11: $150m senior secured corporate loan to Amicus Therapeutics
$150m senior secured corporate loan to Amicus Therapeutics Amicus Corporate Overview Key Products Description: Amicus Therapeutics, Inc. (FOLD) is a biopharmaceutical Fabry disease is a rare, progressive genetic disorder characterized by a company focused on orphan diseases. Amicus markets Galaf
Slide 12: $316m senior secured corporate loan to help finance Sebela's acquisition of Braintree Laboratories
$316m senior secured corporate loan to help finance Sebela’s acquisition of Braintree Laboratories Sebela Corporate Overview Key Products Description: Sebela Pharmaceuticals is a privately-held US Suprep – osmotic laxative indicated for cleansing of the colon focused specialty pharmaceutical com
Slide 13: $150m senior secured corporate loan to Novocure
$150m senior secured corporate loan to Novocure Novocure Corporate Overview Key Products Description: Novocure is a commercial stage oncology company Optune System – a cancer treatment centered on a proprietary developing a profoundly different cancer treatment utilizing a therapy called TTField
Slide 14: $140m-$160m purchase and sale agreement with Bristol Myers Squibb
$140m-$160m purchase and sale agreement with Bristol Myers Squibb Transaction Overview Key Products Description: On 8 December 2017, a wholly-owned subsidiary of FARXIGA (dapagliflozin) – a sodium-glucose cotransporter 2 BPCR entered into a purchase, sale and assignment agreement with (SGLT2) in
Slide 15: $150m senior secured loan to Lexicon
$150m senior secured loan to Lexicon Lexicon Corporate Overview Key Products Description: Lexicon Pharmaceuticals, Inc. (LXRX) is a XERMELO (telotristat ethyl) - an oral treatment that works with biopharmaceutical company focused on developing drugs for cancer, somatostatin analog (SSA) therapy
BioPharma Credit — Investor Presentation (September 2019) on 6ix